Haemonetics Corporation
HAEHealthcareNASDAQMedical Devices · Last scanned Jun 2, 2026
Scan Results
Daily timeframeHaemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company carries a $3.05B market cap, placing it firmly in the mid-cap category. The company operates through Plasma, Blood Center, and Hospital segments.
Market Cap
$3.05B
Beta
0.53
P/E (TTM)
32.79
P/E (Fwd)
11.66
EPS (TTM)
$2.05
EPS (Fwd)
$5.77
ROE
12.0%
ROA
6.5%
Cash
$246.3M
Total Debt
$1.27B
Free CF
$298.1M
52W Change
-3.5%
Annual Financials
Cash vs Debt
The company holds $246.3M in cash, though total debt stands at $1.27B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $298.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 12.0% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 6.5% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $1.17B to $1.33B.
The relatively low beta of 0.53 suggests HAE is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HAE.